{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T15:54:11Z","timestamp":1792166051565,"version":"4.4.0"},"reference-count":56,"publisher":"American Chemical Society (ACS)","issue":"17","license":[{"start":{"date-parts":[[2020,4,24]],"date-time":"2020-04-24T00:00:00Z","timestamp":1587686400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/pubs.acs.org\/page\/policy\/authorchoice_ccbyncnd_termsofuse.html"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,5,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>DNA gyrase and topoisomerase IV are well-validated pharmacological targets, and quinolone antibacterial drugs are marketed as their representative inhibitors. However, in recent years, resistance to these existing drugs has become a problem, and new chemical classes of antibiotics that can combat resistant strains of bacteria are strongly needed. In this study, we applied our hit-to-lead (H2L) chemistry for the identification of a new chemical class of GyrB\/ParE inhibitors by efficient use of thermodynamic parameters. Investigation of the core fragments obtained by fragmentation of high-throughput screening hit compounds and subsequent expansion of the hit fragment was performed using isothermal titration calorimetry (ITC). The 8-(methylamino)-2-oxo-1,2-dihydroquinoline derivative 13e showed potent activity against Escherichia coli DNA gyrase with an IC50 value of 0.0017 \u03bcM. In this study, we demonstrated the use of ITC for primary fragment screening, followed by structural optimization to obtain lead compounds, which advanced into further optimization for creating novel antibacterial agents.<\/jats:p>","DOI":"10.1021\/acsomega.0c00865","type":"journal-article","created":{"date-parts":[[2020,4,24]],"date-time":"2020-04-24T13:43:46Z","timestamp":1587735826000},"page":"10145-10159","source":"Crossref","is-referenced-by-count":68,"title":["Lead Identification of 8-(Methylamino)-2-oxo-1,2-dihydroquinoline\nDerivatives as DNA Gyrase Inhibitors: Hit-to-Lead Generation Involving\nThermodynamic Evaluation"],"prefix":"10.1021","volume":"5","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3122-8625","authenticated-orcid":true,"given":"Fumihito","family":"Ushiyama","sequence":"first","affiliation":[{"name":"Taisho Pharmaceutical Company Ltd. , , 1-403, Yoshino-Cho , Kita-Ku, , ,","place":["Saitama, Saitama, Japan, 331-9530"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideaki","family":"Amada","sequence":"additional","affiliation":[{"name":"Taisho Pharmaceutical Company Ltd. , , 1-403, Yoshino-Cho , Kita-Ku, , ,","place":["Saitama, Saitama, Japan, 331-9530"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoki","family":"Takeuchi","sequence":"additional","affiliation":[{"name":"Taisho Pharmaceutical Company Ltd. , , 1-403, Yoshino-Cho , Kita-Ku, , ,","place":["Saitama, Saitama, Japan, 331-9530"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nozomi","family":"Tanaka-Yamamoto","sequence":"additional","affiliation":[{"name":"Taisho Pharmaceutical Company Ltd. , , 1-403, Yoshino-Cho , Kita-Ku, , ,","place":["Saitama, Saitama, Japan, 331-9530"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harumi","family":"Kanazawa","sequence":"additional","affiliation":[{"name":"Taisho Pharmaceutical Company Ltd. , , 1-403, Yoshino-Cho , Kita-Ku, , ,","place":["Saitama, Saitama, Japan, 331-9530"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koichiro","family":"Nakano","sequence":"additional","affiliation":[{"name":"Taisho Pharmaceutical Company Ltd. , , 1-403, Yoshino-Cho , Kita-Ku, , ,","place":["Saitama, Saitama, Japan, 331-9530"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masashi","family":"Mima","sequence":"additional","affiliation":[{"name":"Taisho Pharmaceutical Company Ltd. , , 1-403, Yoshino-Cho , Kita-Ku, , ,","place":["Saitama, Saitama, Japan, 331-9530"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aiko","family":"Masuko","sequence":"additional","affiliation":[{"name":"Taisho Pharmaceutical Company Ltd. , , 1-403, Yoshino-Cho , Kita-Ku, , ,","place":["Saitama, Saitama, Japan, 331-9530"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iichiro","family":"Takata","sequence":"additional","affiliation":[{"name":"Taisho Pharmaceutical Company Ltd. , , 1-403, Yoshino-Cho , Kita-Ku, , ,","place":["Saitama, Saitama, Japan, 331-9530"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kosuke","family":"Hitaka","sequence":"additional","affiliation":[{"name":"Taisho Pharmaceutical Company Ltd. , , 1-403, Yoshino-Cho , Kita-Ku, , ,","place":["Saitama, Saitama, Japan, 331-9530"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kunihiko","family":"Iwamoto","sequence":"additional","affiliation":[{"name":"Taisho Pharmaceutical Company Ltd. , , 1-403, Yoshino-Cho , Kita-Ku, , ,","place":["Saitama, Saitama, Japan, 331-9530"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Sugiyama","sequence":"additional","affiliation":[{"name":"Taisho Pharmaceutical Company Ltd. , , 1-403, Yoshino-Cho , Kita-Ku, , ,","place":["Saitama, Saitama, Japan, 331-9530"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norikazu","family":"Ohtake","sequence":"additional","affiliation":[{"name":"Taisho Pharmaceutical Company Ltd. , , 1-403, Yoshino-Cho , Kita-Ku, , ,","place":["Saitama, Saitama, Japan, 331-9530"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"316","published-online":{"date-parts":[[2020,4,24]]},"reference":[{"key":"2026090207562671700_cit1","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1128\/cmr.00030-10","article-title":"Challenges\nof Antibacterial Discovery","volume":"24","author":"Silver","year":"2011","journal-title":"Clin. Microbiol.\nRev."},{"key":"2026090207562671700_cit2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1086\/595011","article-title":"Bad Bugs, No Drugs: No ESKAPE! An\nUpdate from the Infectious\nDiseases Society of America","volume":"48","author":"Boucher","year":"2009","journal-title":"Clin. Infect. Dis."},{"key":"2026090207562671700_cit3","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1126\/science.1176667","article-title":"Antibiotics for Emerging Pathogens","volume":"325","author":"Fischbach","year":"2009","journal-title":"Science"},{"key":"2026090207562671700_cit4","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1111\/j.1749-6632.2010.05828.x","article-title":"Challenges of antibacterial\ndiscovery revisited","volume":"1213","author":"Gwynn","year":"2010","journal-title":"Ann. N.Y. Acad. Sci."},{"key":"2026090207562671700_cit5","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1146\/annurev.biochem.70.1.369","article-title":"DNA Topoisomerases:\nStructure, Function, and Mechanism","volume":"70","author":"Champoux","year":"2001","journal-title":"Annu. Rev.\nBiochem."},{"key":"2026090207562671700_cit6","doi-asserted-by":"publisher","first-page":"283","DOI":"10.2174\/1568026033452500","article-title":"The ATP-Binding Site\nof Type II Topoisomerases as a\nTarget for Antibacterial Drugs","volume":"3","author":"Maxwell","year":"2003","journal-title":"Curr. Top. Med.\nChem."},{"key":"2026090207562671700_cit7","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1007\/s00253-011-3557-z","article-title":"Exploiting\nbacterial DNA gyrase as\na drug target: current state and perspectives","volume":"92","author":"Collin","year":"2011","journal-title":"Appl. Microbiol. Biotechnol."},{"key":"2026090207562671700_cit8","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1146\/annurev.biochem.70.1.369","article-title":"DNA TOPOISOMERASES:\nStructure, Function, and Mechanism","volume":"70","author":"Champoux","year":"2001","journal-title":"Annu. Rev.\nBiochem."},{"key":"2026090207562671700_cit9","doi-asserted-by":"publisher","first-page":"2313","DOI":"10.1021\/cr4003984","article-title":"Non-quinolone Inhibitors\nof Bacterial Type IIA Topoisomerases:\nA Feat of Bioisosterism","volume":"114","author":"Mayer","year":"2014","journal-title":"Chem. Rev."},{"key":"2026090207562671700_cit10","doi-asserted-by":"publisher","first-page":"1565","DOI":"10.1021\/bi5000564","article-title":"Mechanism of Quinolone Action and\nResistance","volume":"53","author":"Aldred","year":"2014","journal-title":"Biochemistry"},{"key":"2026090207562671700_cit11","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1007\/s15010-012-0257-2","article-title":"Resistance\nsurveillance studies: a multifaceted problem-the fluoroquinolone example","volume":"40","author":"Dalhoff","year":"2012","journal-title":"Infection"},{"key":"2026090207562671700_cit12","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1038\/nrmicro3380","article-title":"Molecular\nmechanisms of antibiotic resistance","volume":"13","author":"Blair","year":"2015","journal-title":"Nat. Rev.\nMicrobiol."},{"key":"2026090207562671700_cit13","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.1016\/s0140-6736(56)90052-6","article-title":"Two New Antibiotics","volume":"268","author":"Fairbrother","year":"1956","journal-title":"Lancet"},{"key":"2026090207562671700_cit14","doi-asserted-by":"publisher","first-page":"3789","DOI":"10.1021\/ja01571a047","article-title":"The Structure\nof Novobiocin1,2","volume":"79","author":"Hinman","year":"1957","journal-title":"J. Am. Chem. Soc."},{"key":"2026090207562671700_cit15","doi-asserted-by":"publisher","first-page":"2061","DOI":"10.1093\/jac\/dkr247","article-title":"Inhibition\nof DNA gyrase\nand DNA topoisomerase IV of Staphylococcus aureus and Escherichia\ncoli by aminocoumarin antibiotics","volume":"66","author":"Alt","year":"2011","journal-title":"J. Antimicrob.\nChemother."},{"key":"2026090207562671700_cit16","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1021\/id500013t","article-title":"A New-Class\nAntibacterial-Almost. Lessons in Drug Discovery\nand Development: A Critical Analysis of More than 50 Years of Effort\ntoward ATPase Inhibitors of DNA Gyrase and Topoisomerase IV","volume":"1","author":"Bisacchi","year":"2015","journal-title":"ACS Infect. Dis."},{"key":"2026090207562671700_cit17","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.bioorg.2015.07.004","article-title":"Dual targeting\nDNA gyrase B (GyrB)\nand topoisomerse IV (ParE) inhibitors: A review","volume":"62","author":"Azam","year":"2015","journal-title":"Bioorg. Chem."},{"key":"2026090207562671700_cit18","doi-asserted-by":"publisher","first-page":"2033","DOI":"10.2174\/092986707781368414","article-title":"Discovery\nand Development of ATPase\nInhibitors of DNA Gyrase as Antibacterial Agents","volume":"14","author":"Oblak","year":"2007","journal-title":"Curr. Med. Chem."},{"key":"2026090207562671700_cit19","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1080\/13543776.2019.1575362","article-title":"ATP-competitive\nDNA gyrase and topoisomerase IV inhibitors as antibacterial agents","volume":"29","author":"Durcik","year":"2019","journal-title":"Expert Opin. Ther. Pat."},{"key":"2026090207562671700_cit20","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1128\/aac.22.4.662","article-title":"Effects\nof Novobiocin, Coumermycin A1, Clorobiocin, and Their Analogs on Escherichia\ncoli DNA Gyrase and Bacterial Growth","volume":"22","author":"Hooper","year":"1982","journal-title":"Antimicrob.\nAgents Chemother."},{"key":"2026090207562671700_cit21","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1016\/0163-7258(93)90017-8","article-title":"Cyclothialidine and its congeners:\nA new class of DNA gyrase inhibitors","volume":"60","author":"Goetschi","year":"1993","journal-title":"Pharmacol.\nTher."},{"key":"2026090207562671700_cit22","doi-asserted-by":"publisher","first-page":"1695","DOI":"10.1016\/s0960-894x(00)00304-8","article-title":"Improved antibacterial\nactivities of coumarin antibiotics bearing 5\u2032,5\u2032-dialkylnoviose:\nbiological activity of RU79115","volume":"10","author":"Musicki","year":"2000","journal-title":"Bioorg. Med.\nChem. Lett."},{"key":"2026090207562671700_cit23","doi-asserted-by":"publisher","first-page":"e01503","DOI":"10.1128\/aac.01503-18","article-title":"In VitroSusceptibility\nTesting of a Novel Benzimidazole, SPR719, against Nontuberculous Mycobacteria","volume":"62","author":"Brown-Elliott","year":"2018","journal-title":"Antimicrob. Agents Chemother."},{"key":"2026090207562671700_cit24","doi-asserted-by":"publisher","first-page":"6060","DOI":"10.1021\/jm500462x","article-title":"Optimization\nof Pyrrolamide Topoisomerase II Inhibitors Toward Identification of\nan Antibacterial Clinical Candidate (AZD5099)","volume":"57","author":"Basarab","year":"2014","journal-title":"J. Med. Chem."},{"key":"2026090207562671700_cit25","doi-asserted-by":"publisher","first-page":"1240","DOI":"10.1128\/aac.05485-11","article-title":"Pyrrolamide\nDNA Gyrase Inhibitors: Fragment-Based Nuclear Magnetic Resonance Screening\nTo Identify Antibacterial Agents","volume":"56","author":"Eakin","year":"2012","journal-title":"Antimicrob.\nAgents Chemother."},{"key":"2026090207562671700_cit26","doi-asserted-by":"publisher","first-page":"e84409","DOI":"10.1371\/journal.pone.0084409","article-title":"Tricyclic GyrB\/ParE (TriBE) Inhibitors:\nA New Class of Broad-Spectrum Dual-Targeting Antibacterial Agents","volume":"8","author":"Tari","year":"2013","journal-title":"PLoS One"},{"key":"2026090207562671700_cit27","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1006\/abio.1993.1151","article-title":"An Assay Method\nfor DNA Topoisomerase\nActivity Based on Separation of Relaxed DNA from Supercoiled DNA Using\nHigh-Performance Liquid Chromatography","volume":"210","author":"Onishi","year":"1993","journal-title":"Anal.\nBiochem."},{"key":"2026090207562671700_cit28","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.drudis.2014.09.015","article-title":"Evolutions in fragment-based\ndrug design: the deconstruction-reconstruction\napproach","volume":"20","author":"Chen","year":"2015","journal-title":"Drug Discovery Today"},{"key":"2026090207562671700_cit29","doi-asserted-by":"publisher","first-page":"2215","DOI":"10.1021\/acs.jmedchem.6b01576","article-title":"Discovery of First-in-Class,\nPotent, and Orally Bioavailable Embryonic Ectoderm Development (EED)\nInhibitor with Robust Anticancer Efficacy","volume":"60","author":"Huang","year":"2017","journal-title":"J.\nMed. Chem."},{"key":"2026090207562671700_cit30","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1016\/j.drudis.2008.07.005","article-title":"Do Enthalpy\nand Entropy Distinguish First in Class from Best in Class?","volume":"13","author":"Freire","year":"2008","journal-title":"Drug Discovery Today"},{"key":"2026090207562671700_cit31","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1016\/j.drudis.2010.08.013","article-title":"Thermodynamics\nguided lead discovery and optimization","volume":"15","author":"Ferenczy","year":"2010","journal-title":"Drug\nDiscovery Today"},{"key":"2026090207562671700_cit32","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1021\/ml200010k","article-title":"Thermodynamics of\nLigand Binding and Efficiency","volume":"2","author":"Reynolds","year":"2011","journal-title":"ACS Med. Chem.\nLett."},{"key":"2026090207562671700_cit33","doi-asserted-by":"publisher","first-page":"6960","DOI":"10.1021\/acs.jmedchem.5b00812","article-title":"Fragment Binding Can\nBe Either More Enthalpy-Driven or Entropy-Driven: Crystal Structures\nand Residual Hydration Patterns Suggest Why","volume":"58","author":"Ru\u0308hmann","year":"2015","journal-title":"J. Med. Chem."},{"key":"2026090207562671700_cit34","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1016\/j.drudis.2016.01.011","article-title":"Integrating\nbiophysics with HTS-driven drug discovery projects","volume":"21","author":"Folmer","year":"2016","journal-title":"Drug Discovery Today"},{"key":"2026090207562671700_cit35","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1038\/nrd3054","article-title":"Adding calorimetric\ndata to decision\nmaking in lead discovery: a hot tip","volume":"9","author":"Ladbury","year":"2010","journal-title":"Nat. Rev.\nDrug Discovery"},{"key":"2026090207562671700_cit36","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1016\/j.drudis.2006.06.016","article-title":"Hit discovery and\nhit-to-lead approaches","volume":"11","author":"Keseru\u030b","year":"2006","journal-title":"Drug Discovery Today"},{"key":"2026090207562671700_cit37","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1038\/nrd4486","article-title":"Applying thermodynamic\nprofiling in lead finding and optimization","volume":"14","author":"Klebe","year":"2015","journal-title":"Nat. Rev. Drug Discovery"},{"key":"2026090207562671700_cit38","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1038\/nrd.2016.123","article-title":"Biophysics\nin drug discovery: impact,\nchallenges and opportunities","volume":"15","author":"Renaud","year":"2016","journal-title":"Nat. Rev. Drug\nDiscovery"},{"key":"2026090207562671700_cit39","doi-asserted-by":"publisher","first-page":"9663","DOI":"10.1021\/bi970294+","article-title":"The Entropic\nPenalty of Ordered Water Accounts for Weaker Binding of the Antibiotic\nNovobiocin to a Resistant Mutant of DNA Gyrase: A Thermodynamic and\nCrystallographic Study","volume":"36","author":"Holdgate","year":"1997","journal-title":"Biochemistry"},{"key":"2026090207562671700_cit40","doi-asserted-by":"publisher","first-page":"2309","DOI":"10.1038\/nprot.2013.130","article-title":"A three-stage biophysical\nscreening cascade for fragment-based drug discovery","volume":"8","author":"Mashalidis","year":"2013","journal-title":"Nat. Protoc."},{"key":"2026090207562671700_cit41","doi-asserted-by":"publisher","first-page":"6756","DOI":"10.1021\/ac400715t","article-title":"Fragment screening by weak affinity chromatography:\ncomparison with established techniques for screening against HSP90","volume":"85","author":"Meiby","year":"2013","journal-title":"Anal. Chem."},{"key":"2026090207562671700_cit42","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1042\/ebc20170028","article-title":"Current perspectives\nin fragment-based lead discovery\n(FBLD)","volume":"61","author":"Lamoree","year":"2017","journal-title":"Essays Biochem."},{"key":"2026090207562671700_cit43","doi-asserted-by":"publisher","first-page":"8189","DOI":"10.1021\/acs.jmedchem.6b00197","article-title":"Design Principles for Fragment Libraries: Maximizing\nthe Value of Learnings from Pharma Fragment-Based Drug Discovery (FBDD)\nPrograms for Use in Academia","volume":"59","author":"Keseru\u030b","year":"2016","journal-title":"J. Med. Chem."},{"key":"2026090207562671700_cit44","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1016\/j.drudis.2016.11.019","article-title":"Binding\nthermodynamics discriminates fragments from druglike compounds: a\nthermodynamic description of fragment-based drug discovery","volume":"22","author":"Williams","year":"2017","journal-title":"Drug Discovery Today"},{"key":"2026090207562671700_cit45","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1016\/j.bbagen.2014.12.007","article-title":"Thermodynamic signatures\nof fragment binding: Validation of direct\nversus displacement ITC titrations","volume":"1850","author":"Ru\u0308hmann","year":"2015","journal-title":"Biochim.\nBiophys. Acta, Gen. Subj."},{"key":"2026090207562671700_cit46","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1016\/s1359-6446(04)03069-7","article-title":"Ligand efficiency:\na useful metric\nfor lead selection","volume":"9","author":"Hopkins","year":"2004","journal-title":"Drug Discovery Today"},{"key":"2026090207562671700_cit47","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.1128\/aac.50.4.1228-1237.2006","article-title":"In vitro characterization of the\nantibacterial spectrum of novel bacterial type II topoisomerase inhibitors\nof the aminobenzimidazole class","volume":"50","author":"Mani","year":"2006","journal-title":"Antimicrob.\nAgents Chemother."},{"key":"2026090207562671700_cit48","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1128\/aac.00596-06","article-title":"Dual Targeting of GyrB and ParE by\na Novel Aminobenzimidazole Class of Antibacterial Compounds","volume":"51","author":"Grossman","year":"2007","journal-title":"Antimicrob. Agents Chemother."},{"key":"2026090207562671700_cit49","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/s0968-0004(99)01503-0","article-title":"GHKL, an emergent ATPase\/kinase superfamily","volume":"25","author":"Dutta","year":"2000","journal-title":"Trends Biochem. Sci."},{"key":"2026090207562671700_cit50","doi-asserted-by":"publisher","first-page":"3589","DOI":"10.1093\/nar\/9.15.3589","article-title":"DNA gyrase: affinity\nchromatography on novobiocin-Sepharose and catalytic\nproperties","volume":"9","author":"Staudenbauer","year":"1981","journal-title":"Nucleic Acids Res."},{"key":"2026090207562671700_cit51","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1107\/s0021889897006766","article-title":"MOLREP: an Automated Program for\nMolecular Replacement","volume":"30","author":"Vagin","year":"1997","journal-title":"J. Appl. Crystallogr."},{"key":"2026090207562671700_cit52","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1107\/s0907444996012255","article-title":"Refinement\nof Macromolecular Structures\nby the Maximum-Likelihood Method","volume":"53","author":"Murshudov","year":"1997","journal-title":"Acta Crystallogr.,\nSect. D: Biol. Crystallogr."},{"key":"2026090207562671700_cit53","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1016\/j.jep.2012.11.033","article-title":"In vitro anti-Helicobacter pylori\nactivity of a flavonoid rich extract of Glycyrrhiza glabra and its\nprobable mechanisms of action","volume":"145","author":"Asha","year":"2013","journal-title":"J. Ethnopharmacol."},{"key":"2026090207562671700_cit54","doi-asserted-by":"crossref","first-page":"24481","DOI":"10.1016\/S0021-9258(20)80551-1","article-title":"Escherichia coli\ntopoisomerase IV. Purification, characterization,\nsubunit structure, and subunit interactions","volume":"268","author":"Peng","year":"1993","journal-title":"J. Biol. Chem."},{"key":"2026090207562671700_cit55","unstructured":"CLSI.\n          .  Methods for Dilution Antimicrobial Susceptibility Tests\nfor Bacteria That Grow Aerobically; Approved Standard\u2500Tenth\nEdition. CLSI document M07-A10; Clinical\nand Laboratory Standards Institute: Wayne, PA, 2015."},{"key":"2026090207562671700_cit56","unstructured":"CLSI.\n          .  Methods for Antimicrobial Susceptibility Testing of Anaerobic\nBacteria; Approved Standard\u2500Eighth Edition. CLSI document M11-A8; Clinical and Laboratory Standards Institute: Wayne, PA, 2012."}],"container-title":["ACS Omega"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/pubs.acs.org\/doi\/pdf\/10.1021\/acsomega.0c00865","content-type":"application\/pdf","content-version":"vor","intended-application":"unspecified"},{"URL":"https:\/\/pubs.acs.org\/acsodf\/article-pdf\/5\/17\/10145\/67727730\/acsomega.0c00865.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/pubs.acs.org\/acsodf\/article-pdf\/5\/17\/10145\/67727730\/acsomega.0c00865.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T11:56:35Z","timestamp":1788350195000},"score":1,"resource":{"primary":{"URL":"https:\/\/pubs.acs.org\/acsodf\/article\/5\/17\/10145\/616077\/Lead-Identification-of-8-Methylamino-2-oxo-1-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,24]]},"references-count":56,"journal-issue":{"issue":"17","published-online":{"date-parts":[[2020,4,24]]},"published-print":{"date-parts":[[2020,5,5]]}},"URL":"https:\/\/doi.org\/10.1021\/acsomega.0c00865","relation":{},"ISSN":["2470-1343"],"issn-type":[{"value":"2470-1343","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,4,24]]}}}